<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00815945</url>
  </required_header>
  <id_info>
    <org_study_id>AGO-GYN 7</org_study_id>
    <nct_id>NCT00815945</nct_id>
  </id_info>
  <brief_title>Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors</brief_title>
  <official_title>Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AGO Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uterine sarcomas account for less than 5% of all carcinomas of the uterine corpus. The&#xD;
      prognosis of these patients is extremely limited. Recurrence rates of 50-60% are reported&#xD;
      even for early-stage disease (FIGO I/II). Median overall survival is below 12 months in&#xD;
      patients with advanced or metastatic disease.&#xD;
&#xD;
      Ovarian carcinosarcoma is extremely rare among ovarian malignancies (&lt; 2%). That is why there&#xD;
      is insufficient data as a basis for establishing a gold standard. As a result, these cases&#xD;
      tend to be treated in the same way as uterine sarcomas or epithelial ovarian malignancies in&#xD;
      clinical practice.&#xD;
&#xD;
      On the basis of data published to date on the treatment of mixed mesenchymal-epithelial&#xD;
      tumors, it is clear that the treatments commonly used to date have limited activity while&#xD;
      producing clinically relevant toxicity. The regimes verified so far (Cisplatin / Ifosfamide,&#xD;
      Ifosfamide/Paclitaxel and Gemcitabine/Docetaxel) exhibit a considerable side effect spectrum&#xD;
      and are only rarely feasible on clinical everyday life conditions, so e. g. the rate of&#xD;
      withdrawals due to toxicity was in a study collective of selected females treated with the&#xD;
      last combination at 40 %. The physician has to check in every individual case if one of the&#xD;
      above mentioned combinations is feasible. The search for alternative effective and better&#xD;
      tolerated treatment options is essential. The toxicity data on the carboplatin-PLD&#xD;
      combination are known, and efficacy has been identified in small cohorts.&#xD;
&#xD;
      The objective of this study is to explore the efficacy of combination PLD-carboplatin&#xD;
      treatment in a larger patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study in patients with mesenchymal or mixed epithelial mesenchymal tumors of the ovary&#xD;
      or uterus is designed as a prospective single-arm, open - label, multicenter phase II study&#xD;
      to evaluate the efficacy of PegLiposomal Doxorubicin and Carboplatin combination&#xD;
      chemotherapy.&#xD;
&#xD;
      40 patients will be recruited to receive PegLiposomal Doxorubicin (PLD) in a continuous i. v.&#xD;
      infusion of at least 60 minutes at a dose of 40 mg/m2 on Day 1, followed by a 30-minute i. v.&#xD;
      carboplatin infusion according to AUC 6 (formula devised by Calvert et al).&#xD;
&#xD;
      Patients will get outpatients treatment. At screening the patients' eligibility will be&#xD;
      assessed, their baseline and demographic characteristics obtained, and baseline values for&#xD;
      the effect variables collected. Patients with measurable lesions, non-measurable lesions or&#xD;
      histological documentation will be included into this trial. Measurable lesion and&#xD;
      non-measurable lesions will be documented by x-ray, ultrasound, computed tomography or MRI.&#xD;
&#xD;
      The patients' safety will be monitored during therapy until recovery of toxicities.&#xD;
&#xD;
      In patients with measurable lesions at baseline, the (post)-treatment values for effect&#xD;
      according to the RECIST criteria will be collected as shown in table 6. CR, PR and SD have to&#xD;
      be confirmed by a repeat measurement after an interval of at least four weeks.&#xD;
&#xD;
      Follow-up is scheduled every three months during the first two years after the end of&#xD;
      treatment.&#xD;
&#xD;
      As from year 3 the follow-up takes place outside the study in the context of general&#xD;
      aftercare.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anticancer activity in terms of progression-free survival time (PFS)</measure>
    <time_frame>every 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability, i.e. type, frequency, severity and duration of adverse reactions (CTCAE,Version 3.0)</measure>
    <time_frame>until recovery of toxicities</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticancer activity in patients with measurable or evaluable disease in terms of response rates (CR, PR, SD, PD) according to RECIST criteria</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of tumor marker CA-125 with imaging methods</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Mesenchymal Tumor</condition>
  <condition>Carcinosarcoma</condition>
  <condition>Leiomyosarcoma</condition>
  <arm_group>
    <arm_group_label>PegLiposomal Doxorubicin + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive PegLiposomal Doxorubicin (40mg/m²) and Carboplatin (AUC6) every 28 days. Treatment period up to 6 months (therapy can be continued in case of tumor response and benefit for the patient)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PegLiposomal Doxorubicin</intervention_name>
    <description>PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months</description>
    <arm_group_label>PegLiposomal Doxorubicin + Carboplatin</arm_group_label>
    <other_name>Caelyx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin, intravenous, AUC 6, every 28 days for up to 6 months</description>
    <arm_group_label>PegLiposomal Doxorubicin + Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically documented mesenchymal or mixed epithelial-mesenchymal tumor of the&#xD;
             ovary or uterus&#xD;
&#xD;
          -  Patients with a primary diagnosis of FIGO I-IV uterine carcinosarcoma and optimum&#xD;
             debulking (postoperative residual tumor &lt; 1cm) may be enrolled only if&#xD;
             cisplatin-ifosfamide combination therapy is not feasible.&#xD;
&#xD;
          -  Patients with metastatic uterine carcinosarcoma may be enrolled only if&#xD;
             Ifosfamide/Paclitaxel combination therapy is not feasible.&#xD;
&#xD;
          -  Patients with metastatic leiomyosarcoma may be enrolled only if gemcitabine-docetaxel&#xD;
             combination therapy is not feasible.&#xD;
&#xD;
          -  Measurable (target lesion) tumor, evaluable (non-target lesion) tumor or histological&#xD;
             documentation&#xD;
&#xD;
          -  No more than one prior chemotherapy. Any prior platinum or anthracycline- containing&#xD;
             chemotherapy must have been completed more than 6 months previously&#xD;
&#xD;
          -  Prior radiotherapy ≤ 25% of the hematopoietic system is allowed provided it took place&#xD;
             more than 6 weeks before recruitment&#xD;
&#xD;
          -  Patients are allowed to have received prior anticancer hormone therapy or specific&#xD;
             immunotherapy. Patients must have completed these therapies at least three weeks&#xD;
             before recruitment to the study&#xD;
&#xD;
          -  All women with a theoretical possibility of pregnancy must produce a negative&#xD;
             pregnancy test (serum or urinary) within seven days before starting treatment&#xD;
&#xD;
          -  General health of 0 - 2 on the ECOG score&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Estimated life expectancy above 12 weeks&#xD;
&#xD;
          -  At least 3 weeks since major surgery&#xD;
&#xD;
          -  Appropriate hematologic, renal and hepatic function in accordance with the following&#xD;
             definitions:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1.5 × 109 /l&#xD;
&#xD;
          -  Platelets ≥ 100 × 10 9/l&#xD;
&#xD;
          -  Total bilirubin ≤ 1.25 times upper limit of normal&#xD;
&#xD;
          -  Estimated GFR ≥ 50 ml/min&#xD;
&#xD;
          -  LVEF &gt; 50 %&#xD;
&#xD;
          -  Informed consent must be obtained from all patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than one prior chemotherapy (or radiochemotherapy)&#xD;
&#xD;
          -  Active infection or other serious medical impairment liable to affect the patient's&#xD;
             ability to receive treatment according to protocol.&#xD;
&#xD;
          -  Administration of other chemotherapy drugs or other anticancer hormone treatments&#xD;
             during the study.&#xD;
&#xD;
          -  History of clinically manifest atrial or ventricular arrhythmia (&gt; LOWN II) and&#xD;
             congestive heart failure, even if controlled by drugs (NYHA class &gt; II). Documented&#xD;
             myocardial infarction within 6 months before study enrollment.&#xD;
&#xD;
          -  Pregnant or breastfeeding women, or women not practicing appropriate birth control&#xD;
             methods&#xD;
&#xD;
          -  Participation in another study using experimental drugs within the last 30 days&#xD;
&#xD;
          -  Any other conditions or therapies which the physician believes might put the patient&#xD;
             at risk or impair the study objective.&#xD;
&#xD;
          -  Known hypersensitivity to carboplatin or pegylated liposomal doxorubicin&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Harter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Essen Mitte</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité, Campus Virchow Klinikum, Frauenklinik</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malteser Krankenhaus, Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Bonn</city>
        <zip>53123</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte gGmbH, Frauenklinik</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Düsseldorf, Frauenklinik</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Frauenklinik</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J. W. Goethe-Universität, Klinik für Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynäkologisch-onkologische Praxis</name>
      <address>
        <city>Hannover</city>
        <zip>30177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius Kliniken AG, Frauenklinik</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Giessen und Marburg GmbH, Klinik für Gynäkologie, Gynäkologische Endokrinologie und Onkologie</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Großhadern, Frauenklinik</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Frauenklinik</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Universitätsfrauenklinik</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horst Schmidt Kliniken GmbH, Klinik für Gynäkologie und gynäkologische Onkologie</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>December 30, 2008</study_first_submitted>
  <study_first_submitted_qc>December 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2008</study_first_posted>
  <last_update_submitted>February 13, 2017</last_update_submitted>
  <last_update_submitted_qc>February 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leiomyosarcoma</keyword>
  <keyword>carcinosarcoma</keyword>
  <keyword>mixed epithelial mesenchymal tumor</keyword>
  <keyword>endometrial stroma sarcomas</keyword>
  <keyword>Müllerian mixed tumors</keyword>
  <keyword>carcinosarcoma of the uterus</keyword>
  <keyword>mesenchymal tumors of the ovary or uterus</keyword>
  <keyword>mixed epithelial mesenchymal tumors of the ovary or uterus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Carcinosarcoma</mesh_term>
    <mesh_term>Mixed Tumor, Mullerian</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

